You are about to leave Peijia Medical's official Chinese website.
You have just clicked on a link to another website. After clicking Continue, you may be taken to a website run by a third party. We are not responsible for the review and control of content outside Peijia Medical's official Chinese website, nor do we assume any responsibility for business transactions or matters conducted outside Peijia Medical's official Chinese website. The use of other websites is subject to the terms of use and privacy policies of those websites. Certain products or information found on other websites may not be approved for your region or country.
Cancel
Continue
创新速递
公司新闻 创新速递 媒体报道
沛嘉医疗第二代球囊扩张导管TaurusAtlas Pro获批上市
2024-02-01 09:53:36

沛嘉医疗(9996.HK)自主研发的第二代球囊扩张导管—TaurusAtlas Pro球囊扩张导管(下称“TaurusAtlas Pro”)于2024年1月30日,获得中国国家药品监督管理局(NMPA)批准上市,注册证号:国械注准20243030215。沛嘉医疗实时响应临床需求,高质高效完成产品快速迭代升级,该球囊产品的上市,标志着沛嘉医疗在结构心介入领域的产品管线进一步完善。

640.png

TaurusAtlas Pro将供应11个型号,覆盖10-28mm的扩张需求,适配多种术式。TaurusAtlas Pro球囊扩张导管的成功上市,将为临床提供更加完备的产品组合;作为一线术者得心应手的介入治疗武器,进一步提升手术安全性,优化术式流程,提高操作效率。

沛嘉医疗在结构性心脏病领域拥有全面的全球化产品技术布局,涵盖主动脉瓣、二尖瓣、三尖瓣及手术附件等,未来将持续构筑在结构心领域的全线产品研发与生产能力,进一步推动中国瓣膜病介入治疗的技术普及与落地,为更多患者提供安全有效的疾病解决方案。



Top